Key result
Subacromial balloon spacer matches arthroscopic partial repair in improving ASES scores up to 2 years.
Why the study?
Massive irreparable rotator cuff tears are challenging to treat and the efficacy and safety of the arthroscopically inserted biodegradable subacromial balloon spacer require evaluation.
Does an arthroscopically inserted biodegradable subacromial balloon spacer improve shoulder function in patients with massive irreparable rotator cuff tears?
Does an arthroscopically inserted biodegradable subacromial balloon spacer improve shoulder function in patients with massive irreparable rotator cuff tears?
The subacromial balloon spacer provides significant and clinically relevant improvements in shoulder function for patients with massive irreparable rotator cuff tears, comparable to arthroscopic partial repair.
Answers are grounded in this paper and cite their sources.
May support balloon spacer as alternative for massive irreparable tears; leaves open superiority versus partial repair in randomized trials.
Massive irreparable rotator cuff tears (MIRCTs) represent 10% to 40% of cases of rotator cuff abnormality and are challenging to treat. When MIRCTs are unresponsive to nonoperative treatment, surgery may be considered. An arthroscopically inserted biodegradable subacromial balloon spacer (InSpace; Stryker) has grown in popularity in recent years for treatment of patients with MIRCTs. The balloon spacer is made of a copolymer of poly-L-lactide-eco-ε-caprolactone and is expected to fully resorb within 12 months after implantation. Research has suggested the balloon spacer becomes progressively compressed and is slowly replaced with fibrous tissue between the humeral head and the acromion, which may support a prolonged benefit following resorption. Clinical benefits may be achieved through reduced acromiohumeral abutment and subacromial friction during shoulder movement by lowering the humeral head and facilitating humeral gliding. The primary population indicated for use of the implant are patients older than 40 years with persistent shoulder pain and functional disability due to MIRCTs. Contraindications include irreparable subscapularis tears, moderate to severe arthritis, axillary nerve palsy, and known allergy to the implant material. There are not clear indications for use of the implant for treatment of partial-thickness tears or repairable complete rotator cuff tears. Familiari et al. reported that treatment with the balloon spacer was associated with a significant improvement in shoulder function, limited need for revision surgery, and high satisfaction at mean 3-year follow-up. More recently, a prospective multicenter randomized controlled trial was conducted to evaluate the efficacy and safety of the balloon spacer in 93 patients compared to 91 patients undergoing arthroscopic partial repair. Significant and clinically relevant improvements in the American Shoulder and Elbow Surgeons score from baseline were noted in both groups up to the 2-year follow-up.
No takes yet. Share an insight, caveat, or question.
Srikumaran et al. (2023) conducted a review in Massive irreparable rotator cuff tears (MIRCTs) (n=184). Subacromial balloon spacer (InSpace) vs. Arthroscopic partial repair was evaluated on American Shoulder and Elbow Surgeons score. In a trial of 184 patients, the subacromial balloon spacer and arthroscopic partial repair both demonstrated significant improvements in the American Shoulder and Elbow Surgeons score up to 2 years.
Synapse has enriched 10 related papers. Consider them for comparative context: